AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Cambridge Biotech Corp. (CBC), Worcester, Massachusetts, and DynaGen Inc. announced the signing of a letter of intent under which CBC will develop and bring to market DynaGen's proprietary rapid test technologies for tuberculosis and other mycobacteria. CBC will acquire rights to certain of DynaGen's rapid test tuberculosis products. CBC plans to adapt the DynaGen technology to CBC's own patented diagnostic formats. Details of the agreement were not disclosed.